Tocilizumab vs. baricitinib in hospitalized severe COVID-19 patients: results from a real-world cohort.

In-hospital mortality, progression to MV and LOS were not significantly different in patients treated with tocilizumab or baricitinib additionally to standard of care. Both drugs seem equally effective but further head-to-head trials are needed.